Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001104659-24-071265
Filing Date
2024-06-13
Accepted
2024-06-13 16:10:58
Documents
8

Document Format Files

Seq Description Document Type Size
1 424B3 tm2417051d4_424b3.htm 424B3 298259
2 GRAPHIC tm2417051d4_424b3img01.jpg GRAPHIC 11595
3 GRAPHIC tm2331692d1_ex5-1img002.jpg GRAPHIC 2811
4 GRAPHIC tm2331692d1_ex5-1img001.jpg GRAPHIC 31114
5 GRAPHIC tm2331692d1_ex99-2img007.jpg GRAPHIC 7024
6 GRAPHIC tm2331692d1_ex99-2img005.gif GRAPHIC 3765
7 GRAPHIC tm2331692d1_ex99-2img003.jpg GRAPHIC 2165
8 GRAPHIC tm2331692d1_ex99-2img002.jpg GRAPHIC 3361
  Complete submission text file 0001104659-24-071265.txt   385618
Mailing Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5
Business Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5 403-607-2621
XORTX Therapeutics Inc. (Filer) CIK: 0001729214 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-258741 | Film No.: 241041343
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)